Cyclo Therapeutics Inc
NASDAQ:CYTH
Intrinsic Value
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. [ Read More ]
The intrinsic value of one CYTH stock under the Base Case scenario is 0.56 USD. Compared to the current market price of 1.41 USD, Cyclo Therapeutics Inc is Overvalued by 60%.
Valuation Backtest
Cyclo Therapeutics Inc
Run backtest to discover the historical profit from buying and selling CYTH stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Cyclo Therapeutics Inc
Current Assets | 12.3m |
Cash & Short-Term Investments | 9.2m |
Receivables | 122.4k |
Other Current Assets | 2.9m |
Non-Current Assets | 929.3k |
PP&E | 929.3k |
Current Liabilities | 8.5m |
Accounts Payable | 7.5m |
Accrued Liabilities | 1m |
Non-Current Liabilities | 22.5k |
Other Non-Current Liabilities | 22.5k |
Earnings Waterfall
Cyclo Therapeutics Inc
Revenue
|
1.1m
USD
|
Cost of Revenue
|
-98.5k
USD
|
Gross Profit
|
978k
USD
|
Operating Expenses
|
-21m
USD
|
Operating Income
|
-20.1m
USD
|
Other Expenses
|
-7.3k
USD
|
Net Income
|
-20.1m
USD
|
Free Cash Flow Analysis
Cyclo Therapeutics Inc
CYTH Profitability Score
Profitability Due Diligence
Cyclo Therapeutics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Cyclo Therapeutics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
CYTH Solvency Score
Solvency Due Diligence
Cyclo Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
Cyclo Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CYTH Price Targets Summary
Cyclo Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for CYTH is 3.26 USD with a low forecast of 2.63 USD and a high forecast of 4.2 USD.
Ownership
CYTH Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CYTH Price
Cyclo Therapeutics Inc
Average Annual Return | -50.85% |
Standard Deviation of Annual Returns | 35.79% |
Max Drawdown | -99% |
Market Capitalization | 40.3m USD |
Shares Outstanding | 28 720 000 |
Percentage of Shares Shorted | 0.22% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. The company is headquartered in Gainesville Florida, Florida and currently employs 9 full-time employees. The company went IPO on 2004-02-27. The firm's lead drug candidate, Trappsol Cyclo (hydroxypropyl beta cyclodextrin) is for the treatment of Niemann-Pick Type C disease (NPC). NPC is a rare and fatal cholesterol metabolism disease that impacts the brain, lungs, liver, spleen, and other organs. The company is also focusing on the use of cyclodextrins in the treatment of Alzheimer's disease. The firm's product lines include Trappsol and Aquaplex. The company sells its chemical products directly to customers in the pharmaceutical, diagnostics, and industrial chemical industries, and to chemical supply distributors. The firm also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.
Contact
IPO
Employees
Officers
The intrinsic value of one CYTH stock under the Base Case scenario is 0.56 USD.
Compared to the current market price of 1.41 USD, Cyclo Therapeutics Inc is Overvalued by 60%.